Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• This invention relates to phenylbenzimidazole analogs that inhibit prohferation of tumor cells in vitro and in vivo.
• This family of small molecules is useful in treating conditions associated with uncontrolled cell proliferation which characterizes many forms of cancer.
• - ⁇ biological processes Cellular proliferation occurs in all living organisms and involves two main processes: nuclear division (mitosis), and cytoplasmic division (cytokinesis). Because organisms are continually growing and replacing cells, cellular proliferation is essential to the vitality of the healthy cell. However, disruption of normal cellular proliferation can result in a variety of disorders. For example, hyperproliferation of cells may cause psoriasis, thrombosis, atherosclerosis, coronary heart disease, myocardial infarction, stroke, smooth muscle neoplasms, uterine fibroid or fibroma, and obliterative diseases of vascular grafts and transplanted organs. Abnormal cell proliferation is most commonly associated with tumor formation and cancer.
• Cancer is a major disease and is one of the leading causes of mortality world-wide. Indeed, cancer is the second leading cause of death in the United States. According to the National Institute of Health, the overall annual cost for cancer is approximately $107 billion, which includes $37 billion for direct medical costs, $11 billion for indirect costs of lost productivity due to illness and $59 billion for indirect costs of lost productivity due to premature death. Not su ⁇ risingly, considerable efforts are underway to develop new treatments and preventative measures to comb' this devastating illness.
• Chemotherapy involves the use of chemical agents to disrupt the replicate a ⁇ d metabolism of cancerous cells.
• Chemotherapeutic agents which are currently being usec 70 *- ⁇ ea - cancer can be classified into the following main groups: alkylating drugs, antimetabolites,- nu t umor antibiotics, plant alkaloids, and steroid hormones. /
• One embodiment relates to a family of phenylbenzimidazole derivatives tb/ l ⁇ ibit cell prohferation. These phenylbenzimidazole derivatives were first described in U.. Patent Nos. 6,271,390; 6,303,645; and 6,369,091 and co-pending U.S. Application Nos. (9/983,054; and
• the preferred embodiments are related to the use of families of related compounds for the treatment of cancer.
• the phenylbenzimidazole inhibitors of tumor growth in accordance with the preferred embodiments are represented by Genuses A-F, as shown below.
• Genus A One family of small molecule inhibitors, designated Genus A, in accordance with preferred embodiments includes compounds defined by Formula IX:
• X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, tbiomorpholine, nitroj cyano, CF 3 , OCF 3 , CORi, COORi, CONH 2 , CONHRj, and HCORi; n is an integer from one to three; m is an integer from one to four; ⁇
• R is selected from the group consisting of H, CH 3 , C 2 H 5 , C 3 H 7 , H 9 , CH 2 Ph, CBb EL t - F(p-), COCH 3 , COCH 2 CH 3 , CH 2 CH 2 N(CH 3 ) 2 , and CH 2 CH 2 CH 2 N(CH 3 ) 2 ; and
• Ri and R 2 are independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, polycycloalkyl, substituted polycycloalkyl, polycycloalkenyl, substituted polycycloalkenyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylcycloalkyl, substituted heteroarylcycloalkyl, heterocyclic ring, substituted heterocyclic ring, heteroatom, and substituted heteroatom.
• Genus B Another family of small molecule inhibitors, designated Genus B, in accordance with preferred embodiments includes compounds defined by Formula IX:
• X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, atkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF 3 , OCF 3 , CORi, COORi, CONH 2 , CONHRi, andNHCORi; n is an integer from one to three; m is an integer from one to four;
• R is selected from the group consisting of H, CH 3 , C 2 H 5 , C 3 H 7 , C 4 H 9 , CH 2 Ph, CFkC ⁇ EU- F(p-), COCH 3 , COCH 2 CH 3 , CH 2 CH 2 N(CH 3 ) 2 , and CH 2 CH 2 CH 2 N(CH 3 ) 2 ; and
• Ri and R 2 are independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, polycycloalkyl, substituted polycycloalkyl, polycycloalkenyl, substituted polycycloalkenyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylcycloalkyl, and substituted heteroarylcycloalkyl, heterocyclic ring, substituted heterocyclic ring, heteroatom, substituted heteroatom, aryl, and substituted aryl, wherein at least one of Ri and R 2 is selected from aryl or substituted aryl.
• Genus C Another family of small molecule inhibitors, designated Genus C, in accordance with preferred embodiments includes compounds defined by Formula X:
• X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF 3 , OCF 3 , COR l5 COORi, CONH 2 , CONHRi, andNHCORi; n is an integer from one to four; m is an integer from one to four;
• R is selected from the group consisting of H, CH 3 , C 2 H 5 , C 3 H 7 , G 1 H 9 , CH 2 Ph, CFtC ⁇ EL . - F(p-), COCH3, COCH 2 CH 3 , CH 2 CH 2 N(CH 3 ) 2 , and CH 2 CH 2 CH 2 N(CH 3 ) 2 ; and
• a and B rings independently comprise unsubstituted or substituted carbon atoms ranging from four carbon atoms to ten carbon atoms.
• Genus D One family of small molecule inhibitors, designated Genus D, in accordance with preferred embodiments includes compounds defined by Formula XI:
• X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF 3 , OCF 3 , CORi, COORi, CONH 2 . CONHRi, andNHCORi; n is an integer from one to three; m is an integer from one to five; R is selected from the group consisting of H, CH 3 , Q 2 H 5 , C 3 H 7 , H 9 , CH 2 Ph,
• R ! is selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, polycycloalkyl, substituted polycycloalkyl, polycycloalkenyl, substituted polycycloalkenyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylcycloalkyl, and substituted heteroarylcycloalkyl, aryl, substituted aryl, heterocyclic ring, substituted heterocyclic ring, heteroatom, " and substituted heteroatom.
• Genus E One family of small molecule inhibitors, designated Genus E, in accordance with preferred embodiments includes compounds defined by Formula XII:
• X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, benzo, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF 3 , OCF 3 , COR 2 , COOR 2 , CONH 2 , CONHR 2 , andNHCOR 2 ; n is an integer from one to four; m is an integer from one to four; R is selected from the group consisting of H, CH 3 , C 2 H 5> C 3 H 7 , H 9 , CH 2 Ph,
• R 2 is selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, polycycloalkyl, substituted polycycloalkyl, polycycloalkenyl, substituted polycycloalkenyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylcycloalkyl, and substituted heteroarylcycloalkyl, aryl, substituted aryl, heterocyclic ring, substituted heterocyclic ring, heteroatom, and substituted heteroatom.
• Genus F One family of small molecule inhibitors, designated Genus F, in accordance with preferred embodiments includes compounds defined by Genuses A, B, and C collectively.
• a method for treating a disease condition associated with abnormal cell proHferation in a mammal comprises the step of administering to a mammal an effective amount of a pharmaceutical formulation for treating a disease condition associated with
• 'abnormal cell proliferation comprising at least one benzimidazole compound from the above-disclosed small molecule families of Genuses A-F.
• the small molecule anti-cell proliferation compound may be administered in conjunction with at least one additional agent, which is active in reducing a symptom associated with cell proliferation.
• the small molecule inhibitor may be mixed with at least one additional active ingredient to form a pharmaceutical composition.
• the small molecule inhibitor may be co-administered at the same time or according to different treatment regimens with the at least one additional active agent.
• the benzimidazole compound may be administered in conjunction with at least one additional active agent.
• active agents include antiiungals, antivirals, antibiotics, anti-inflammatories, and anticancer agents.
• Anticancer agents include, but are not limited to, alkylating agents (lomustine, carmustine, streptozocin, mecMoremamine, melphalan, uracil nitrogen mustard, chlorambucil cyclophosphamide, iphosphamide, cisplatin, carboplatin mitomycin thiotepa dacarbazine procarbazine, hexamethyl melamine, triethylene melamine, busulfan, pipobroman, and mitotane); antimetabolites (methotrexate, trimetrexate pentostatin, cytarabine, ara-CMP, fludarabine phosphate, hydroxyurea, fluorouracil, floxuridine, chlorodeoxyaden
• the benzimidazole compounds of the preferred embodiments are administered in conjunction with one or more other therapies.
• These therapies include, but are not limited to radiation, immu ⁇ otherapy, gene therapy and surgery.
• These combination therapies may be administered simultaneously or sequentially.
• radiation may be administered along with the administration of benzimidazole compounds, or may be administered at any time before or after administration of benzimidazole compounds.
• a dose of about 0.01 mg to about 100 mg per kg body weight per day of the small molecule anti-cell proliferation compound is preferably administered in divided doses daily.
• the methods provided herein for treating diseases and processes mediated by undesired, uncontrolled or abnormal cell proliferation, such as cancer involve administering to a mammal a composition of the benzimidazole compounds disclosed herein to inhibit cell prohferation.
• the method is particularly useful for preventing or treating tumor formation and progression.
• the compounds and methods disclosed are especially useful in treating estrogen receptor positive and estrogen receptor negative type breast cancers.
• Figure 1 shows a graph of the suppression of spleen cell prohferation responses by AVP XXX.
• Spleen cell cultures were established from na ⁇ ve BALB/c mice and incubated for about 4 days in the presence of stimulus and active compound. Cultures were pulsed for about 4 hours with 3 H-thymidine and harvested.
• Figure 2 shows a graph of the suppression of spleen cell proliferation responses by AVP
• YYY Spleen cell cultures were established from na ⁇ ve BALB/c mice and incubated for about 4 days in the presence of stimulus and active compound. Cultures were pulsed for about 4 hours with 3 H-thymidine and harvested.
• Figure 3 shows a graph of effect of AVP YYY on the proliferation of M12.4.1 cells in vitro.
• M12.4.1 cells were cultured at about 3000,000 per ml in the presence and absence of active compound and stimulus for about 2 days.
• 3 H-thymidine was added to the cultures for about the final 6 hours before harvesting.
• Figure 4 shows a graph of effect of AVP XXX and AVP YYY on the prohferation of M12.4.1 cells in the presence of IL-4/anti-CD40 antibody. 3 H-thymidine was added to the cultures for about the final 6 hours before harvesting.
• Figure 5 shows a table of the cell lines used in the cell proliferation experiments.
• Figure 6 shows a graph of the cell line prohferation to AVP XXX and AVP YYY in vitro. Cells were cultured overnight in the presence of active compound and pulsed with 3 H-thymidine for about 4 to about 12 hours before harvesting. IC 50 s of 800 nM denote greater than or equal to 800nM.
• Figure 7 shows a graph of the proliferation response of human breast cancer cell lines to
• AVP XXX and AVP YYY were cultured overnight in the presence of active compound and pulsed with 3 H-thymidine for about 4 to about 12 hours before harvesting.
• IC 50 s of 800 nM denote greater than or equal to 800nM.
• the preferred embodiments are directed to small molecules which are useful in the treatment of diseases associated with abnormal cellular proliferation, including, but not limited to, tumorigenesis and other proliferative diseases such as, but not limited to, cancers, inflammatory disorders, and circulatory diseases.
• diseases associated with abnormal cellular proliferation including, but not limited to, tumorigenesis and other proliferative diseases such as, but not limited to, cancers, inflammatory disorders, and circulatory diseases.
• hype ⁇ roliferation of cells can cause psoriasis, thrombosis, atherosclerosis, coronary heart disease, myocardial infarction, stroke, smooth muscle neoplasms, uterine fibroid or fibroma, and obliterative diseases of vascular grafts and transplanted organs.
• Abnormal cell proliferation is most commonly associated with tumor formation and cancer.
• the particular compounds disclosed herein were identified by their ability to suppress abnormal cellular proliferation.
• T cells were depleted prior to culture by incubating spleen cells first with a cocktail of anti-Thyl ascites (10%), anti-CD4 Ab (0.5 ⁇ g/ml) and anti-CD8 Ab (0.5 ⁇ g/ml), followed by guinea pig complement (adsorbed).
• M12.4.5 cells and Vero cells were unstimulated. All cells were cultured for 2 days and pulsed with 3 H-thymidine during the final 4 to 6 hrs of culture.
• the mixed lymphocyte reaction involved administration of 2 mg/kg/day or 5 mg/kg/day of AVP XXX (a representative compound of Genus B) or AVP YYY (a representative compound of Genus A), or vehicle daily for 4 days to BALB/c mice and removing their spleens 24 hr after the last dose.
• Spleen cells from C57BL/6 mice were prepared for use, as stimulator cells following removal of. red blood cells by ACK treatment and irradiating for 2.6 min (250 rads).
• Stimulator cells C57BL/6) were cultured at 5 X 10 s cells/ml and r sponder cells (BALB/c) at 2 X 10 5 cells/ml.
• Certain compounds of the preferred embodiments suppressed B cell proliferation responses to PMA ionomycin and IL-4/anti-CD40 Ab ( Figures 1 and 2) with approximately the same potencies as they suppress in vitro responses to IL-4/anti-CD40 Ab (not shown). Similar inhibition potencies were obtained for AVP XXX in ConA-stimulated T cell prohferation and LPS-stimulated B cell prohferation, suggesting a lack of specificity in the action of these drugs. On the other hand, a battery of immunological tests performed with AVP XXX demonstrated little other effects other than inhibition of ConA-stimulated cytokine release.
• Tumor Cells The results with splenic lymphocytes led to a further analysis of cellular prohferation by measuring the growth of tumor cells in the presence of these drugs.
• the initial analysis was performed with murine Ml 2.4.1 lymphoma cells, either unstimulated or stimulated with IL-4/anti- CD40 Ab.
• both AVP XXX and AVP YYY suppressed the prohferation of M12.4.1 cells but with lower potency that observed in stimulated spleen cells.
• the potency of both compounds increased when the cells were cultured with E -4/anti- CD40 Ab. This stimulation is known to induce the activity of NF- ⁇ B in M12.4.1 cells.
• AVP XXX and AVP YYY exert an anti-proliferative activity to T and B lymphocytes exposed to a variety of immunogenic stimuli in vitro. These actions are highly potent and parallel their IgE-suppression activity. Although the mechamsm of this action is unresolved, much is known about the mechanism of IL-4/anti-CD40 Ab-induced IgE production. A major factor in this response is the transcription activator, NF- ⁇ B. This factor has been implicated in the proliferation of a number of tumor cells and thus these drugs were tested for activity on the proliferation of various tumor cell lines in vitro.
• alkyl refers to a monovalent straight or branched chain radical of from one to ten carbon atoms, including, but not limited to, methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, tert-butyl, n-hexyl, and the like.
• alkoxy refers to straight or branched chain alkyl group covalently bonded to the parent molecule through an — O ⁇ linkage.
• alkoxy radicals include, but are limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, n-butoxy, sec-butoxy, t-butoxy and the like.
• alkenyl used herein refers to a monovalent straight or branched chain radical of from two to six carbon atoms containing a carbon double bond including, but not limited to, 1- propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl, and the like.
• alkynyl used herein refers to a monovalent straight or branched chain radical of from two to six carbon atoms containing a carbon triple bond including, but not limited to, 1- propynyl, 1-butynyl, 2-butynyl, and the like.
• aryl refers to homocyclic aromatic radical whether fused or not fused.
• aryl groups include, but are not limited to, phenyl, naphthyl, biphenyl, phenanthrenyl, naphthacenyl, and the like.
• cycloalkyl used herein refers to saturated aliphatic ring system radical having 3 to 10 carbon atoms including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl, and the like.
• cycloalkenyl used herein refers to aliphatic ring system radical having 3 to 10 carbon atoms having at least one carbon-carbon double bond in the ring. Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclopentenyl, cyclohexenyl, and the like.
• polycycloalkyl refers to saturated aliphatic ring system radical having at least two rings that are fused with or without bridgehead carbons.
• examples of polycycloalkyl groups include, but are not limited to, bicyclo[4.4.0]decanyl, bicyclo[2.2.1]heptanyl, adamantanyl, norbornyl, and the like.
• polycycloalkenyl used herein refers to aliphatic ring system radical having at least two rings that are fused with or without hridghead carbons in which at least one of the rings has a carbon-carbon double bond.
• polycycloalkenyl groups include, but are not limited to, norbornylenyl, 1 , 1 '-bicyclopentenyl, and the like.
• heterocyclic used herein refers to cyclic ring system radical having at least one ring system in which one or more ring atoms are not carbon, namely heteroatom. Heterocycles can be nonaromatic or aromatic. Examples of heterocyclic groups include, but are not limited to, mo ⁇ holinyl, oxazolyl, pyranyl, pyridyl, pyrimidinyl, pyrrolyl, and the like.
• heteroaryl refers to heterocyclic radical formally derived from an arene by replacement of one or more methine andor vinylene groups by trivalent or divalent heteroatoms, respectively, in such a way as to maintain the aromatic system.
• heteroaryl groups include, but are hot limited to, pyridyl, pyrrolyl, oxazolyl, indolyl, and the like.
• arylalkyl refers to one or more aryl groups appended to an alkyl radical.
• arylalkyl groups include, but are not limited to, benzyl, phenethyl, phenpropyl, phenbutyl, and the like.
• heteroarylalkyl refers to one or more heteroaryl groups appended to an alkyl radical.
• arylcycloalkyl used herein refers to one or more aryl groups appended to a cycloalkyl radical.
• heteroarylcycloalkyl used herein refers to one or more heteroaryl groups appended to a cycloalkyl radical.
• Genus A One family of small molecule inhibitors, designated Genus A, in accordance with preferred embodiments includes compounds defined by Formula IX:
• X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomo ⁇ holine, nitro, cyano, CF 3 , OCF 3 , CORi, COORi, CONH 2 , CONHRi, andNHCORi; n is an integer from one to three; m is an integer from one to four;
• R is selected from the group consisting of H, CH 3 , C 2 H 5 , C 3 H 7 , H 9 , CH 2 Ph, CR C ⁇ £ - F(p-), COCH 3 , COCH 2 CH 3 , CH 2 CH 2 N(CH 3 ) 2 , and CH 2 CH 2 CH 2 N(CH 3 ) 2 ; and
• Ri and R 2 are independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, polycycloalkyl, substituted polycycloalkyl, polycycloalkenyl, substituted polycycloalkenyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylcycloalkyl, substituted heteroarylcycloalkyl, heterocyclic ring, substituted heterocyclic ring, heteroatom, and substituted heteroatom.
• Genus B Another family of small molecule inhibitors, designated Genus B, in accordance with preferred embodiments includes compounds defined by Formula DC: wherein:
• X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, mo ⁇ holine, thiomo ⁇ holine, nitro, cyano, CF 3 , OCF 3 , CORi, COORi, CONH 2 , CONHRi, and NHCORj; n is an integer from one to three; m is an integer from one to four;
• R is selected from the group consisting of H. CH 3 , C 2 H 5 , C 3 H 7 , H 9 , CH 2 Ph, CH. 2 C£ - F(p-), COCH3, COCH 2 CH 3 , CH 2 CH 2 N(CH 3 ) 2 , and CH 2 CH 2 CH 2 N(CH 3 ) 2 ; and
• Ri and R 2 are independently selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, polycycloalkyl, substituted polycycloalkyl, polycycloalkenyl, substituted polycycloalkenyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylcycloalkyl, and substituted heteroarylcycloalkyl, heterocyclic ring, substituted heterocychc ring, heteroatom, substituted heteroatom, aryl, and substituted aryl, wherein at least one of Ri and R 2 is selected from aryl or substituted aryl.
• Genus C Another family of small molecule inhibitors, designated Genus C, in accordance with preferred embodiments includes compounds defined by Formula X:
• X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, mo ⁇ holine, thiomo ⁇ holine, nitro, cyano, CF 3 , OCF 3 , CORi, COOR CONH 2 ,
• n is an integer from one to four;
• m is an integer from one to four;
• R is selected from the group consisting of H, CH 3 , C 2 H 5 , C 3 H 7 , H , CH 2 Ph, CHkCeH-j- F(p-), COCH 3 , COCH 2 CH 3 , CH 2 CH 2 N(CH 3 ) 2 , and CH 2 CH 2 CH 2 N(CH 3 ) 2 ; and
• a and B rings independently comprise unsubstituted or substituted carbon atoms ranging from four carbon atoms to ten carbon atoms.
• Genus D One family of small molecule inhibitors, designated Genus D, in accordance with preferred embodiments includes compounds defined by Formula XI:
• X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, mo ⁇ holine, thiomo ⁇ holine, nitro, cyano, CF 3 , OCF 3 , CORi, COORi, CONH 2 , CONHRi, and NHCORi ; n is an integer from one to three; m is an integer from one to five;
• R is selected from the group consisting of H, CH 3 , C 2 H 5 , C 3 H 7 , H 9 , CH 2 Ph, CH ⁇ I ,- F(p-), COCH 3 , COCH 2 CH 3 , CH 2 CH 2 N(CH 3 ) 2 , and CH 2 CH 2 CH 2 N(CH 3 ) 2 ; and
• Ri is selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, polycycloalkyl, substituted polycycloalkyl, polycycloalkenyl, substituted polycycloalkenyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylcycloalkyl, and substituted heteroarylcycloalkyl, aryl, substituted aryl, heterocychc ring, substituted heterocychc ring, heteroatom, and substituted heteroatom.
• Genus E One family of small molecule inhibitors, designated Genus E, in accordance with preferred embodiments includes compounds defined by Formula XH: wherein:
• X and Y may be different or the same and are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, benzo, hydroxy, amino, alkylamino, cycloalkyl, mo ⁇ holine, thiomo ⁇ holine, nitro, cyano, CF 3 , OCF 3 , COR 2 , COOR 2 , CONH 2 , CONHR 2 , and NHCOR 2 ; n is an integer from one to four; m is an integer from one to four;
• R is selected from the group consisting of H, CH 3 , C 2 H 5 , C 3 H 7 , H 9 , CH 2 Ph, CH 2 C 6 H 4 - F(p-), COCH 3 , COCH 2 CH 3 , CH 2 CH 2 N(CH 3 ) 2 , and CH 2 CH 2 CH 2 N(CH 3 ) 2 ; and R 2 is selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, polycycloalkyl, substituted polycycloalkyl, polycycloalkenyl, substituted polycycloalkenyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, arylcycloalkyl, substituted arylcyclo
• Genus F One family of small molecule inhibitors, designated Genus F, in accordance with preferred embodiments includes compounds defined by Genuses A, B, and C collectively.
• the substituents on the preceding groups hsted in Genuses A-F can be selected from alkyl, alkenyl, alkynyl, aryl, heterocychc ring, trihalomethyl, carboxy, oxo, alkoxycarbonyl, alkoxylate, formyl, amido, halo, hydroxy, alkoxy, amino, alkylamino, cyano, nitro, imino, azido, thio, thioalkyl, sulfoxide, sulfone, or sulfate.
• the compounds of the preferred embodiments can possess at least one basic functional substituent and, as such, are capable of forming salts. Included in the definition of pharmaceutically acceptable salts are the relatively non-toxic, inorganic, and organic base or acid addition salts of the compounds of the preferred embodiments.
• Representative salts include those selected from the group comprising; acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, camsylate, carbonate, chloride, clavulanate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycoilylarsanllate, hexylresorcinate, hydrab-imine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, malseate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, palmirate, pantothenate, phosphat
• Certain compounds of the invention possess one or more chiral centers and may thus exist in optically active forms.
• the compounds contain an alkenyl or alkenylene group there exists the possibility of cis- and trans- isomeric forms of the compounds.
• the R- and S- isomers and mixtures thereof, including racemic mixtures as well as mixtures of cis- and trans- isomers, are contemplated.
• Additional asymmetric carbon atoms can be present in a substituent group, such as an alkyl group. All such isomers as well as the mixtures thereof are intended to be included in the preferred embodiments.
• a particular stereoisomer is desired, it can be prepared by methods well known in the art by using stereospecific reactions with starting materials which contain the asymmetric centers and are already resolved or, alternatively by methods which lead to mixtures of the stereoisomers and subsequent resolution by known methods.
• HPLC/MS data was obtained using a Gilson semi-prep HPLC with a Gilson 170 Diode Array UV detector and PE Sciex API 100LC MS based detector.
• a Waters 600E with a Waters 490E UN detector was also used for recording HPLC data.
• the compounds were eluted with a gradient of CH 3 C ⁇ (with 0.0035% TFA) and H20 (with 0.01% TFA).
• Both HPLC instruments used Advantage C18 60A 5 ⁇ 50mm x 4.6mm col ⁇ mns from Thomson Instrument Company. Mass spectra were obtained by direct injection and electrospray ionization on a PE Sciex API 100LC MS
• the compounds of the preferred embodiments were prepared using the following synthetic reactions shown in Synthetic Scheme 1, wherein the desired acid chlorides are selected from the R t and R 2 groups provided in Table 1.
• the numbers that refer to the compounds in the text below correspond to those in the diagram.
• Compounds 1 and 2 can have the appropriate substituents to ultimately give a desired product 6 with the corresponding substituents.
• the positions of the amides on the phenylbenzimidazole ring in a desired product 6 can be varied according the position of the nitrogen on the rings in the starting materials.
• Table 1 discloses representative acid chlorides and does not represent all the possible acid chlorides that can be used.
• Phenylbenzimidazole 5 was dissolved in dry pyridine in a scintillation vial and a desired acid chloride (1.1 eq) was added slowly. The reactions were carried out in an oven at 60°C After 16h, the reaction was cooled to RT and DI water was added. Precipitation took place, which was filtered off, washed with water and air-dried. The aqueous layer was extracted with EtOAc, dried over anhydrous Na 2 SO and the solvent was removed in vacuo to result in diamido product 6.
• the diamido-phenylbenzimidazole compounds of the preferred embodiments can also be prepared using the following synthetic reactions shown in Synthetic Scheme 2, wherein the desired acid chlorides are selected from the R groups provided in Table 1.
• the numbers that refer to the compounds in the text below correspond to those in the diagram.
• Compounds 11 and 12 can have the appropriate substituents to ultimately give a desired product 15 with the corresponding substituents.
• the positions of the amides on the phenylbenzimidazole ring in the desired product 15 can be varied according tot he position of the nitrogen on the rings of the starting -materials.
• -Table 1 discloses representative acid chlorides and does not represent all the possible acid chlorides that can be used.
• the one type of acid chloride is used to form the amides on both amines of 14.
• the compounds of the preferred embodiments were generally prepared from 2-(4- ammophenyl)-5-aminobenzimidazole, which was obtained by reduction of 2-(4-nitrophenyl)-5- nitrobenzimidazole.
• the dinitro phenylbenzimidazole 13 was prepared as follows: a mixture of 4- nitrophenylenethamine (6.4g, 41.83 mmol) and 4-nitrobenzoic acid (7.86 g, 47 mmol) was dissolved in POCl 3 (250 ml) and heated to reflux for 2 h. The reacti ⁇ h mixture was cooled, poured on to ice, and stirred for 30 min.
• the resulting solid as filtered and washed with methanol and sodium bicarbonate to remove unreacted acid and allowed to dry overnight to give the desired product as a brown solid (5.8g).
• the product was characterized by electrospray mass spectroscopy (mp >300° C). . ..
• 2-(4-Aminophenyl)-5-aminobenzimidazole 14 was prepared by suspending the above solid (75 g) in THF (75 ml), to which was added Pd-C (10% Pd by weight). Thd flask was purged with hydrogen and stirred under a balloon of hydrogen overnight. TLC and MS showed starting material was still present so the reaction was allowed to continue over the weekend. TLC indicated complete reaction, the reaction was filtered through celite and washed with methanol. The solvent was removed under reduced pressure to give a dark brown solid (0.37 g) that was used without further purification.
• the 2-(4-arrjinophenyl)-5-aminobenzimidazole 14 was prepared by the following reduction: 2-(4-nitrophenyl)-6-nitrobenzimidazole (8.9 g, 31 mmole) was suspended in concentrated HCl (100 ml) to which was added sta ⁇ nous chloride (42.3 g 180 mmole). The reaction mixture was heated to reflux for 5 hrs. The mixture was cooled to RT and the HCl salt of the desired product was precipitated by the addition of ethanol. The resulting solid was filtered, re- dissolved in water and the solution made basic by the addition of concentrated ammonium hydroxide.
• the resulting precipitate was filtered and dried overnight under vacuum to yield the desired product as a gray solid (6.023 g, 26.9 mmole, 87%).
• the product was characterized by electrospray mass spectroscopy and HPLC (mp. 222-227° C).
• the intermediate 14 is diacylated to form the diamido- phenylbenzimidazole by the above procedures according to Synthetic Scheme 1.
• the monoamido-phenylbenzimidazole compounds of the preferred embodiments can be prepared using the following synthetic reactions shown in Synthetic Scheme 3, wherein the desired acid chlorides are selected from the Ri groups provided in Table 1.
• the numbers that refer to the compounds in the text below correspond to those in the diagram.
• Compounds 21 and 22 can have the appropriate substituents to ultimately give a desired product 25 with the corresponding substituents.
• the position of the amide on the phenylbenzimidazole ring in the desired product 25 can be varied according to the postion of the nitrogen on ]the ring in the starting materials.
• Table 1 discloses representative acid chlorides and does not represent all the possible acid chlorides that can be used.
• the intermediate 24 can be formed from the condensation of phenylenediamine and 4-aminobenzoic acid Synthetic Scheme 3
• the mono-imido-phenylbenzimidazole compounds of the preferred embodiments can also be prepared vising the following synthetic reactions shown in Synthetic Scheme 4, wherein the desired acid chlorides are selected from the Ri groups provided in Table 1.
• the numbers that refer to the compounds in the text below correspond to those in the diagram.
• Compounds 31 and 32 can have the appropriate substituents to ultimately give a desired product 35 with the corresponding substituents.
• Table 1 discloses representative acid chlorides and does not represent all the possible acid chlorides that can be used.
• the intermediate 34 can be formed from the condensation of r ⁇ ro-phenylenediamine and benzoic acid
• the compounds of the Genus C of preferred embodiments can be prepared using the following synthetic reactions shown in Synthetic Scheme 5.
• an amino substituent of compound 3 or 42 is reacted with an acyl chloride with a latent carboxylic acid at the other end.
• the carboxylic acid is revealed and coupled with the amide in the presence of 2- dimethylaminoisopropyl chloride hydrochloride (DIC), 1-hydroxybenzotriazole hydrate (HOBt), triethylamine and methylene chloride.
• DIC 2- dimethylaminoisopropyl chloride hydrochloride
• HOBt 1-hydroxybenzotriazole hydrate
• triethylamine triethylamine
• n and m are integers representing the number of unsubstituted or substituted methylene groups.
• the compounds of the preferred embodiments can be administered to a patient either alone or a part of a pharmaceutical composition.
• the compositions can be administered to patients either orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), intracistemally, intravaginally, intraperitoneally, intravesically, locally (powders, ointments, or drops), or as a buccal or nasal spray.
• compositions suitable for parenteral injection can comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
• suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include, but are not limited to, water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters, such as ethyl oleate.
• Proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
• These compositions can also contain adjuvants, such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It can also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, ahmiinum monostearate and gelatin.
• Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
• the active compound is admixed with at least one inert customary excipient (or carrier), such as sodium citrate or dicalcium phosphate or
• fillers or extenders as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid
• binders as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia
• humectants as for example, glycerol
• disintegrating agents as for example, agar- agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate
• solution retarders as for example paraffin
• absorption accelerators as for example, quaternary ammonium compounds
• wetting such as sodium citrate or dicalcium phosphate
• compositions of a similar type can also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like.
• Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They can contain opacifying agents, and can also be of such composition that they release the active compoimd or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used are polymeric substances and waxes. The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above- mentioned excipients.
• Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
• the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan or mixtures of these substances, and the like.
• inert diluents commonly used in the art, such as water or other solvents, solubilizing
• composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
• adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
• Suspensions in addition to the active compounds, can contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or ⁇ mixtures of these substances, and the like.
• suspending agents as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or ⁇ mixtures of these substances, and the like.
• compositions for rectal administrations are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable non-irritating excipients or carriers, such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
• suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
• Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants.
• the active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required.
• Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope.
• the compounds of the preferred embodiments can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
• the compounds of the preferred embodiments can exist in different stereoisomeric forms by virtue of the presence of asymmetric centers in the compounds. It is contemplated that all stereoisomeric forms of the compounds, as well as mixtures thereof including racemic mixtures, form part of the preferred embodiments.
• the preferred embodiments cover compounds made either using standard organic synthetic techniques, including combinatorial chemistry or by biological methods, such as through metabolism.
• the small molecule anti-cell proliferation compound may be administered in conjunction with at least one additional agent, which is active in reducing a symptom associated with cell prohferation.
• the small molecule inhibitor may be mixed with at least one additional active ingredient to form a pharmaceutical composition.
• the small molecule inhibitor may be co-administered at the same time or according to different treatment regimens with the at least one additional active agent.
• the benzimidazole compound may be administered in conjunction with at least one additional active agent.
• active agents include antifungals, antivirals, antibiotics, anti-inflammatories, and anticancer agents.
• Anticancer agents include, but are not limited to, alkylating agents (lomustine, carmustine, streptozocin, mecUoremamine, melphalan, uracil nitrogen mustard, chlorambucil cyclophosphamide, iphosphamide, cisplatin, carboplatin mitomycin thiotepa dacarbazine procarbazine, hexamethyl melamine, triethylene melamine, busulfan, pipobroman, and mitotane); antimetabolites (methotrexate, trimetrexate pentostatin, cytarabine, ara-CMP, fludarabine phosphate, hydroxyurea, fluorouracil, floxuridine, chlorodeoxyadeno
• the benzimidazole compounds of the preferred embodiments are administered in conjunction with one or more other therapies.
• These therapies include, but are not limited to radiation, immunotherapy, gene therapy and surgery.
• These combination therapies may be administered simultaneously or sequentially.
• radiation may be administered along with the administration of benzimidazole compounds, or may be administered at any time before or after administration of benzimidazole compounds.
• the compounds and pharmaceutical compositions can be used in the treatment of hyperproliferative disorders in mammals, including humans.
• disorders include, but are not limited to, tumorigenesis and other proliferative diseases such as, but not limited to, cancers, inflammatory disorders, and circulatory diseases.
• hyperproliferation of cells can cause psoriasis, thrombosis, atherosclerosis, coronary heart disease, myocardial infarction, stroke, smooth muscle neoplasms, uterine fibroid or fibroma, and obliterative diseases of vascular grafts and transplanted organs.
• Abnormal cell proliferation is most commonly associated with tumor formation and cancer.
• Methods of use include a step of administering a therapeutically effective amount of an active ingredient to a mammal in need thereof.
• the compounds of the preferred embodiments are administered in the form of a pharmaceutical formulation.
• the compounds can be administered orally, parenterally, topically, rectally, etc., in appropriate dosage units, as desired.
• Actual dosage levels of active ingredients in the pharmaceutical compositions can be varied so as to administer an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient.
• the compounds of the preferred embodiments can be administered to a patient at dosage levels in the range of about 0.1 to about 1000 mg per day.
• dosage levels in the range of about 0.1 to about 1000 mg per day.
• a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is preferable.
• the selected dosage level will depend upon the activity of the particular compound, the route of adrxiinistration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated.
• the effective daily dose can be divided into multiple doses for purposes of administration, e.g., two to four separate doses per day.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=28675384

Family Applications (1)

Country Status (9)

Cited By (47)

Families Citing this family (19)

Family Cites Families (34)

• 2003
  • 2003-02-26 TW TW092104005A patent/TW200304820A/zh unknown
  • 2003-03-06 EP EP03711459A patent/EP1494668A4/en not_active Withdrawn
  • 2003-03-06 CA CA002479453A patent/CA2479453A1/en not_active Abandoned
  • 2003-03-06 US US10/508,968 patent/US20050197375A1/en not_active Abandoned
  • 2003-03-06 AU AU2003213768A patent/AU2003213768A1/en not_active Abandoned
  • 2003-03-06 WO PCT/US2003/006981 patent/WO2003082186A2/en not_active Ceased
  • 2003-03-06 JP JP2003579729A patent/JP2005525389A/ja active Pending
  • 2003-03-25 UY UY27732A patent/UY27732A1/es not_active Application Discontinuation
  • 2003-03-25 PE PE2003000304A patent/PE20040165A1/es not_active Application Discontinuation

Also Published As

Similar Documents

Legal Events